Jellagen founded in 2013, is a UK Marine Biotechnologies Company based in Cardiff, whose strategic mission is to utilise sustainable marine species and natural resources, to develop technical and scientific high value products, meeting state of the art specifications. The first products developed by Jellagen are based on Next Generation Collagen extracted from Jellyfish. These products developed through this new technology, are cell culture reagents used to grow stem cells in 2D and 3D by the Biotech and Pharma Industry R&D teams.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

KD PHARMA GROUP AND HERBOLEA BIOTECH SIGN LICENSING AGREEMENT FOR USE OF BIO-HERBOLYSIS™ EXTRACTION TECHNOLOGY

KD Pharma Group | June 24, 2020

news image

The KD Pharma Group SA ("KD Pharma"), a global pharmaceutical CMO and one of the leading producers of Omega-3 fatty acids, and Herbolea Biotech Srl ("Herbolea"), an Italian biotechnology company developing proprietary botanical extraction technologies, are pleased to announce the signing of a Licensing Agreement granting KD Pharma the rights to utilize Herbolea's Bio-Herbolysis™ extraction technology in Europe.Bio-Herbolysis™ is a highly scalable, solven...

Read More

MEDTECH

SALIPRO BIOTECH RECEIVES EUROPEAN PATENT FOR ANTIGEN PRODUCTION

Salipro Biotech | February 09, 2022

news image

Swedish biotech company Salipro Biotech AB announced that the European Patent Office has granted a further European Patent to the company, No. EP 3 043 814 B1 entitled "Antigen and method for production thereof", following the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2. The patents cover the composition-of-matter, methods and uses of the company's novel antigen technology, strengthening Salipro Biotech's proprietary platform te...

Read More

CELL AND GENE THERAPY

PULMATRIX ANNOUNCES PATIENT DOSING COMPLETED FOR ITS NOVEL INHALED THERAPY PUR3100 FOR ACUTE MIGRAINE

Pulmatrix, Inc. | September 27, 2022

news image

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

Read More

AI

WHITELAB GENOMICS AND THE ACCELERATOR FOR TECHNOLOGICAL RESEARCH IN GENOMIC THERAPIES COLLABORATE ON AI FOR GENE THERAPY BIOPRODUCTION

WhiteLab Genomics | June 01, 2021

news image

As part of this collaboration, teams from the Accelerator for Technological Research in Genomic Therapies (ART-TG, Inserm US35) and WhiteLab Genomics will use the WhiteLab Genomics CatalystTM platform to generate a database specific to the bioproduction of lentiviral vectors, which will be used to identify the parameters allowing for a significant increase in vector quality as well as their production yields, and to reduce the production costs. Cell and gene therapy is a new biome...

Read More
news image

KD PHARMA GROUP AND HERBOLEA BIOTECH SIGN LICENSING AGREEMENT FOR USE OF BIO-HERBOLYSIS™ EXTRACTION TECHNOLOGY

KD Pharma Group | June 24, 2020

The KD Pharma Group SA ("KD Pharma"), a global pharmaceutical CMO and one of the leading producers of Omega-3 fatty acids, and Herbolea Biotech Srl ("Herbolea"), an Italian biotechnology company developing proprietary botanical extraction technologies, are pleased to announce the signing of a Licensing Agreement granting KD Pharma the rights to utilize Herbolea's Bio-Herbolysis™ extraction technology in Europe.Bio-Herbolysis™ is a highly scalable, solven...

Read More
news image

MEDTECH

SALIPRO BIOTECH RECEIVES EUROPEAN PATENT FOR ANTIGEN PRODUCTION

Salipro Biotech | February 09, 2022

Swedish biotech company Salipro Biotech AB announced that the European Patent Office has granted a further European Patent to the company, No. EP 3 043 814 B1 entitled "Antigen and method for production thereof", following the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2. The patents cover the composition-of-matter, methods and uses of the company's novel antigen technology, strengthening Salipro Biotech's proprietary platform te...

Read More
news image

CELL AND GENE THERAPY

PULMATRIX ANNOUNCES PATIENT DOSING COMPLETED FOR ITS NOVEL INHALED THERAPY PUR3100 FOR ACUTE MIGRAINE

Pulmatrix, Inc. | September 27, 2022

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

Read More
news image

AI

WHITELAB GENOMICS AND THE ACCELERATOR FOR TECHNOLOGICAL RESEARCH IN GENOMIC THERAPIES COLLABORATE ON AI FOR GENE THERAPY BIOPRODUCTION

WhiteLab Genomics | June 01, 2021

As part of this collaboration, teams from the Accelerator for Technological Research in Genomic Therapies (ART-TG, Inserm US35) and WhiteLab Genomics will use the WhiteLab Genomics CatalystTM platform to generate a database specific to the bioproduction of lentiviral vectors, which will be used to identify the parameters allowing for a significant increase in vector quality as well as their production yields, and to reduce the production costs. Cell and gene therapy is a new biome...

Read More